The monoclonal antibody, rituximab, is used to treat lymphomas. This article discusses the results of randomized trials that suggest patients with follicular lymphoma should not receive rituximab maintenance therapy.
This is a preview of subscription content, log in via an institution to check access.
References
Hainsworth, J. D. et al. Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase II trial of the Minnie Pearl Cancer Research Network. J. Clin. Oncol. 21, 1746–1751 (2003).
Ghielmini, M. et al. Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with weekly ×4 schedule. Blood 103, 4416–4423 (2004).
Hochster, H. et al. Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progession-free survival in advanced indolent lymphoma: results of the randomized phase III ECOG1496 study. J. Clin. Oncol. 27, 1607–1614 (2009).
Forstpointner, R. et al. Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG). Blood 108, 4003–4008 (2006).
van Oers, M. H. et al. Rituximab maintenance improves clinical outcome of relapsed/refractory follicular non-Hodgkin's lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase III intergroup trial. Blood 108, 3295–3301 (2006).
Van Oers, M. H. J. et al. Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin's lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study [abstract 836]. Blood 112, 309–310 (2008).
Vidal, L. et al. Rituximab maintenance for the treatment of patients with follicular lymphma: systematic review and meta-analysis of randomized trials. J. Natl Cancer Inst. 101, 248–255 (2009).
Hainsworth, J. D. et al. Maximizing therapeutic benefit of rituximab: maintenance therapy versus retreatment at progression in patients with indolent non-Hodgkin's lymphoma: a randomized phase II trial of the Minnie Pearl Cancer Research Network. J. Clin. Oncol. 23, 1088–1095 (2005).
Habermann, T. M. et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J. Clin. Oncol. 24, 3121–3127 (2006).
Morschhauser, F. et al. Phase III trial of consolidation therapy with 90Y-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma. J. Clin. Oncol. 26, 5156–5164 (2008).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
B. Cheson is a Consultant for Celgene, Roche and Genetech and is on the Speakers' Bureau for Celgene.
Rights and permissions
About this article
Cite this article
Cheson, B. The case against rituximab maintenance. Nat Rev Clin Oncol 6, 622–624 (2009). https://doi.org/10.1038/nrclinonc.2009.161
Issue Date:
DOI: https://doi.org/10.1038/nrclinonc.2009.161
- Springer Nature Limited
This article is cited by
-
Rituximab maintenance for follicular lymphoma
Nature Reviews Clinical Oncology (2010)
-
Author reply: Rituximab maintenance for follicular lymphoma
Nature Reviews Clinical Oncology (2010)
-
Correction: The case against rituximab maintenance
Nature Reviews Clinical Oncology (2009)